Current Research Studies

Cancer - NANT 2011-04: A Phase I Study of Lenalidomide and Anti-GD2 Mab CH14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma

Condition or Therapy:



Cancer and blood disorders

What is the goal of this study?

This study looks at how well the combination of lenalidomide and dinutuximab work in treating patients with or without the drug isotretinoin who have refractory or recurrent neuroblastoma.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are up to 21 years old and
  • Have recurrent or refractory neuroblastoma

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Navin Pinto